Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Lesinurad (sodium)

Catalog No: tcsc3478

Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg

Size: 200mg

Specifications

CAS No:
1151516-14-1

Formula:
$C_{17}H_{13}BrN_3NaO_2S$

Pathway:
Membrane Transporter/Ion Channel

Target:
URAT1

Purity / Grade:
>98%

Solubility:
DMSO : ≥ 26 mg/mL (61.00 mM)

Alternative Names:
RDEA-594 sodium

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Observed Molecular Weight:
426.26

Product Description

Lesinurad sodium is a **URAT1** and **OAT** inhibitor, is determined to be a substrate for the kidney transporters **OAT1** and **OAT3** with **K m** values of 0.85 and 2 μM, respectively.

IC50 & Target: Km: 0.85 μM (OAT1), 2 μM (OAT3)[1]

In Vitro: Lesinurad is a novel selective uric acid reabsorption inhibitor (SURI). Lesinurad is determined to be a substrate for the kidney transporters organic anion transporter (OAT1) and OAT3 with K_m values of 0.85 and 2 μM, respectively[1]. Lesinurad (RDEA594) is a URAT1 and OAT inhibitor, which increases proximal renal tubule urate excretion[2]. Lesinurad (RDEA594) is a potential uric acid lowering agent througn inhibition of uric acid reuptake, and exhibits favorable p450 profiles, inhibits CYP2C9 and CYP2C8 with IC_{50} of 14.4 μM and 16.2 μM, respectively. IC_{50}s of Lesinurad are all above 100 μM for CYP1A2, CYP2C19,and CYP2D6[3].

In Vivo: Lesinurad (RDEA594) shows better pharmacokinetics than its pro-drug RDEA806. The 100 mg dose of Lesinurad exhibits a phamacological effect in the range of that produced by 300 mg to 800 mg single doses of RDEA806[3].